{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:13:52Z","timestamp":1781835232818,"version":"3.54.5"},"reference-count":217,"publisher":"Elsevier","isbn-type":[{"value":"9780128046906","type":"print"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1016\/bs.acc.2015.10.005","type":"book-chapter","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T16:39:15Z","timestamp":1452789555000},"page":"127-168","source":"Crossref","is-referenced-by-count":47,"title":["Biochemistry of Statins"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2015.10.005_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/VHRM.S1653","article-title":"Clinical efficacy and safety of statins in managing cardiovascular risk","volume":"4","author":"Kapur","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/bs.acc.2015.10.005_bb0010","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.acc.2015.10.005_bb0015","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0021-9258(19)51290-X","article-title":"Ultracentrifugal studies of lipoproteins of human serum","volume":"179","author":"Gofman","year":"1949","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2015.10.005_bb0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1126\/science.111.2877.166","article-title":"The role of lipids and lipoproteins in atherosclerosis","volume":"111","author":"Gofman","year":"1950","journal-title":"Science"},{"key":"10.1016\/bs.acc.2015.10.005_bb0025","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1749-6632.1956.tb36833.x","article-title":"Serum lipoproteins and the evaluation of atherosclerosis","volume":"64","author":"Gofman","year":"1956","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/bs.acc.2015.10.005_bb0030","first-page":"e6","article-title":"Heart disease and stroke statistics\u20142013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2015.10.005_bb0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: a critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/bs.acc.2015.10.005_bb0045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0002-9459(24)08821-1","article-title":"\u2018Teachers\u2019 topics: antihyperlipidemic statins: a self-contained, clinically relevant medicinal chemistry lesson","volume":"69","author":"Roche","year":"2005","journal-title":"Am. J. Pharm. Educ."},{"key":"10.1016\/bs.acc.2015.10.005_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1567-5688(03)00004-7","article-title":"Comparative pharmacology of rosuvastatin","volume":"4","author":"McTaggart","year":"2003","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/bs.acc.2015.10.005_bb0055","series-title":"Drug Therapy for Hypercholesterolemia and Dyslipidemia","author":"Brunton","year":"2011"},{"key":"10.1016\/bs.acc.2015.10.005_bb0060","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/009127000204200902","article-title":"A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin","volume":"42","author":"White","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0065","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1016\/j.bmcl.2007.05.096","article-title":"Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors","volume":"17","author":"Pfefferkorn","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/bs.acc.2015.10.005_bb0070","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"10.1016\/bs.acc.2015.10.005_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/1043-6618(95)80042-5","article-title":"Pharmacology of competitive inhibitors of HMG-CoA reductase","volume":"31","author":"Corsini","year":"1995","journal-title":"Pharmacol. Res."},{"key":"10.1016\/bs.acc.2015.10.005_bb0080","unstructured":"N. Biljana, M. Ana, S. Miranda, A Review of Current Trends and Advances in Analytical Methods for Determination of Statins: Chromatography and Capillary Electrophoresis."},{"key":"10.1016\/bs.acc.2015.10.005_bb0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/clpt.1990.136","article-title":"Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia","volume":"48","author":"Pan","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0095","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/j.1552-4604.1996.tb04224.x","article-title":"Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening","volume":"36","author":"Cilla","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0100","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/ajhp\/52.15.1639","article-title":"Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors","volume":"52","author":"Garnett","year":"1995","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/bs.acc.2015.10.005_bb0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","article-title":"Hydrophilicity\/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors","volume":"19","author":"Hamelin","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/bs.acc.2015.10.005_bb0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/0049825031000066259","article-title":"Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin","volume":"33","author":"Nezasa","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/bs.acc.2015.10.005_bb0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1358\/mf.2003.25.6.769652","article-title":"Clinical pharmacokinetics of statins","volume":"25","author":"Garcia","year":"2003","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0120","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0125","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/03602539009041088","article-title":"Physiological disposition of HMG-CoA-reductase inhibitors","volume":"22","author":"Duggan","year":"1990","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/bs.acc.2015.10.005_bb0130","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/archinte.160.15.2273","article-title":"Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians","volume":"160","author":"Bottorff","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","article-title":"Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences","volume":"32","author":"Lennernas","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.acc.2015.10.005_bb0145","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/bs.acc.2015.10.005_bb0150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00003088-200039060-00002","article-title":"Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events","volume":"39","author":"Hatanaka","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.acc.2015.10.005_bb0155","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1053\/j.gastro.2013.03.055","article-title":"Statins and cancer in gastroenterology: new insight?","volume":"144","author":"Gazzerro","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.acc.2015.10.005_bb0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-5793(76)80996-9","article-title":"Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity","volume":"72","author":"Endo","year":"1976","journal-title":"FEBS Lett."},{"key":"10.1016\/bs.acc.2015.10.005_bb0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0885-4505(92)90060-C","article-title":"Biosynthesis and characterization of (S)-and (R)-3-hydroxy-3-methylglutaryl coenzyme A","volume":"48","author":"Bischoff","year":"1992","journal-title":"Biochem. Med. Metab. Biol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/bs.acc.2015.10.005_bb0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2362.1994.tb00984.x","article-title":"Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors","volume":"24","author":"Sehayek","year":"1994","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/bs.acc.2015.10.005_bb0180","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00005-009-0038-5","article-title":"Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases","volume":"57","author":"Chow","year":"2009","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"10.1016\/bs.acc.2015.10.005_bb0185","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins\u2014basic research and clinical perspectives","volume":"74","author":"Zhou","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/bs.acc.2015.10.005_bb0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10408363.2013.813013","article-title":"Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy","volume":"50","author":"Egom","year":"2013","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/bs.acc.2015.10.005_bb0195","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0022-2275(20)38144-X","article-title":"Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins","volume":"23","author":"Miettinen","year":"1982","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2015.10.005_bb0200","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11883-002-0060-0","article-title":"A general assessment of the safety of HMG CoA reductase inhibitors (statins)","volume":"4","author":"Black","year":"2002","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/bs.acc.2015.10.005_bb0205","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/bs.acc.2015.10.005_bb0210","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/j.1875-9114.1998.tb03905.x","article-title":"A comparison of fluvastatin 40mg every other day versus 20mg every day in patients with hypercholesterolemia","volume":"18","author":"Rindone","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/bs.acc.2015.10.005_bb0215","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0002-8703(02)00140-0","article-title":"Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS)","volume":"144","author":"Matalka","year":"2002","journal-title":"Am. Heart J."},{"key":"10.1016\/bs.acc.2015.10.005_bb0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/107424840300800205","article-title":"Efficacy of alternate-day dosing versus daily dosing of atorvastatin","volume":"8","author":"Jafari","year":"2003","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00592-006-0216-4","article-title":"Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia","volume":"43","author":"Ferrer-Garcia","year":"2006","journal-title":"Acta Diabetol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0230","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1345\/aph.1H124","article-title":"Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia","volume":"40","author":"Wongwiwatthananukit","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/bs.acc.2015.10.005_bb0235","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","article-title":"Once-a-week rosuvastatin (2.5 to 20mg) in patients with a previous statin intolerance","volume":"103","author":"Ruisinger","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0240","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/ajhp\/57.18.1703","article-title":"Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic","volume":"57","author":"Fugit","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/bs.acc.2015.10.005_bb0245","first-page":"465","article-title":"Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center","volume":"5","author":"Patel","year":"1999","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/bs.acc.2015.10.005_bb0250","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1345\/aph.1D391","article-title":"Approximate equivalent rosuvastatin doses for temporary statin interchange programs","volume":"38","author":"Kendrach","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/bs.acc.2015.10.005_bb0255","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0260","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.acc.2015.10.005_bb0265","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/bs.acc.2015.10.005_bb0270","series-title":"Johns Hopkins HIV Guide 2012","author":"Gallant","year":"2012"},{"key":"10.1016\/bs.acc.2015.10.005_bb0275","unstructured":"www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm200635.htm (accessed on February 19)."},{"key":"10.1016\/bs.acc.2015.10.005_bb0280","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0285","unstructured":"Product information for Livalo. Kowa Pharmaceuticals America IM, AL 36117. February 2012."},{"key":"10.1016\/bs.acc.2015.10.005_bb0290","unstructured":"PL Detail-Document, OATP Fruit Juice Drug Interactions. Pharmacist's Letter\/Prescriber's Letter. June 2011."},{"key":"10.1016\/bs.acc.2015.10.005_bb0295","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0025-7125(16)30184-5","article-title":"Drug treatment of dyslipoproteinemia","volume":"78","author":"Larsen","year":"1994","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/bs.acc.2015.10.005_bb0300","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1994.00420140051007","article-title":"Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial","volume":"154","author":"Illingworth","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0305","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0310","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/14779072.1.4.495","article-title":"Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia","volume":"1","author":"Rosenson","year":"2003","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0315","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0320","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0735-1097(98)00300-3","article-title":"Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin","volume":"32","author":"Brown","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0325","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-120-7-199404010-00002","article-title":"Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients","volume":"120","author":"Sprecher","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0330","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0335","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0340","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9149(00)00942-5","article-title":"Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels","volume":"86","author":"Kastelein","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0345","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2337\/dc08-1681","article-title":"Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study","volume":"32","author":"Rosenson","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/bs.acc.2015.10.005_bb0350","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","article-title":"Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I","volume":"79","author":"Davidson","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0355","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jama.1996.03530260042029","article-title":"Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia","volume":"275","author":"Bakker-Arkema","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9149(97)00280-4","article-title":"A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia","volume":"80","author":"Dart","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0365","unstructured":"R. Rosenson, Statins: Actions, Side Effects, and Administration. UpToDate, Topic 4564, Version 43.0."},{"key":"10.1016\/bs.acc.2015.10.005_bb0370","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0009-9236(01)25429-0","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0375","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0380","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","article-title":"Safety and efficacy of statins in Asians","volume":"99","author":"Liao","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0385","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/01.CIR.103.7.926","article-title":"Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization","volume":"103","author":"Crisby","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2015.10.005_bb0390","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0735-1097(97)00537-8","article-title":"Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys","volume":"31","author":"Williams","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0395","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/01.CIR.104.3.249","article-title":"Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging","volume":"104","author":"Corti","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2015.10.005_bb0400","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/01.CIR.0000041255.88750.F0","article-title":"Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years\u2019 follow-up by high-resolution noninvasive magnetic resonance imaging","volume":"106","author":"Corti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2015.10.005_bb0405","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0410","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1210\/jcem.85.6.6642-1","article-title":"Hyperlipidemia: diagnostic and therapeutic perspectives","volume":"85","author":"Ballantyne","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2015.10.005_bb0415","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0420","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0425","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0430","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0435","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","article-title":"Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants","volume":"170","author":"Ray","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0440","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0445","first-page":"S1","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2015.10.005_bb0450","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0455","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0460","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/M14-0112","article-title":"Controversy over clinical guidelines: listen to the evidence, not the noise","volume":"160","author":"Guallar","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0465","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)62388-0","article-title":"Statins: new American guidelines for prevention of cardiovascular disease","volume":"382","author":"Ridker","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0470","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jama.2013.284203","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence","volume":"311","author":"Psaty","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0475","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2014.2634","article-title":"The new cholesterol and blood pressure guidelines: perspective on the path forward","volume":"311","author":"Krumholz","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0480","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/jama.2013.281355","article-title":"Accumulating evidence for statins in primary prevention","volume":"310","author":"Robinson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0485","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jama.2015.7434","article-title":"Cholesterol lowering in 2015: still answering questions about how and in whom","volume":"314","author":"Greenland","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0490","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.2015.7515","article-title":"Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events","volume":"314","author":"Pursnani","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0495","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11883-014-0438-9","article-title":"A look at statin cost-effectiveness in view of the 2013 ACC\/AHA cholesterol management guidelines","volume":"16","author":"Deano","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/bs.acc.2015.10.005_bb0500","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease","volume":"314","author":"Pandya","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0505","first-page":"843","article-title":"Benefits of statin therapy and compliance in high risk cardiovascular patients","volume":"6","author":"Lardizabal","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/bs.acc.2015.10.005_bb0510","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0515","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0520","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0530","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archinte.164.13.1427","article-title":"Effectiveness of statin therapy in adults with coronary heart disease","volume":"164","author":"Wilt","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0535","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0540","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0545","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/0003-4819-137-7-200210010-00015","article-title":"Can statins cause chronic low-grade myopathy?","volume":"137","author":"Grundy","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0550","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/bs.acc.2015.10.005_bb0555","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0560","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/eci.12461","article-title":"The role of mitochondria in statin-induced myopathy","volume":"45","author":"Apostolopoulou","year":"2015","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/bs.acc.2015.10.005_bb0565","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20291","article-title":"Molecular clues into the pathogenesis of statin-mediated muscle toxicity","volume":"31","author":"Baker","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/bs.acc.2015.10.005_bb0570","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2165\/00002018-200629080-00007","article-title":"Effect of ezetimibe and\/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial","volume":"29","author":"Berthold","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/bs.acc.2015.10.005_bb0575","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0009-9236(95)90266-X","article-title":"Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans","volume":"57","author":"Laaksonen","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0580","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0585","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archneur.61.6.889","article-title":"Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke","volume":"61","author":"Rundek","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0590","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0595","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1067\/mhj.2001.116762","article-title":"The effect of pravastatin and atorvastatin on coenzyme Q10","volume":"142","author":"Bleske","year":"2001","journal-title":"Am. Heart J."},{"key":"10.1016\/bs.acc.2015.10.005_bb0600","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0002-9149(97)89180-1","article-title":"The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle","volume":"77","author":"Laaksonen","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0605","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme Q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0610","series-title":"Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease","author":"(UK) NCGC","year":"2014"},{"key":"10.1016\/bs.acc.2015.10.005_bb0615","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2015.10.005_bb0620","first-page":"923","article-title":"HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats","volume":"46","author":"Sugiyama","year":"1998","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/bs.acc.2015.10.005_bb0625","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5551\/jat.12.111","article-title":"Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients","volume":"12","author":"Mabuchi","year":"2005","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/bs.acc.2015.10.005_bb0630","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking MELAS syndrome. A case report","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur. Neurol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0635","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00018-006-6235-z","article-title":"Toxicity of statins on rat skeletal muscle mitochondria","volume":"63","author":"Kaufmann","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/bs.acc.2015.10.005_bb0640","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.freeradbiomed.2011.10.449","article-title":"Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes","volume":"52","author":"Kwak","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0645","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","article-title":"Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy","volume":"79","author":"Mullen","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0650","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1998.8491","article-title":"Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study","volume":"152","author":"Nakahara","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0655","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.taap.2003.08.013","article-title":"Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats","volume":"194","author":"Schaefer","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0660","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2131\/jts.36.445","article-title":"Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats","volume":"36","author":"Obayashi","year":"2011","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/bs.acc.2015.10.005_bb0665","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/eurheartj\/ehr224","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a \u2018mitohormesis\u2019 mechanism involving reactive oxygen species and PGC-1","volume":"33","author":"Bouitbir","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2015.10.005_bb0670","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.1996.04178.x","article-title":"Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio","volume":"42","author":"De Pinieux","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0675","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0680","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2012.12.023","article-title":"Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy","volume":"325","author":"Stringer","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/bs.acc.2015.10.005_bb0685","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12020-008-9126-2","article-title":"Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids","volume":"35","author":"Phillips","year":"2009","journal-title":"Endocrine"},{"key":"10.1016\/bs.acc.2015.10.005_bb0690","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbrc.2009.08.008","article-title":"Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression","volume":"388","author":"Iacobazzi","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.acc.2015.10.005_bb0695","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.bbrc.2005.02.070","article-title":"Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle","volume":"329","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.acc.2015.10.005_bb0700","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/jpet.105.086462","article-title":"Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells","volume":"314","author":"Sacher","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/bs.acc.2015.10.005_bb0705","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2015.10.005_bb0710","first-page":"635","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0715","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(05)61628-5","article-title":"Polymyositis associated with simvastatin","volume":"349","author":"Giordano","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0720","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00124743-200110000-00019","article-title":"A case of atorvastatin combined toxic myopathy and inflammatory myositis","volume":"7","author":"Folzenlogen","year":"2001","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0725","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/anr.1780320324","article-title":"The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis","volume":"32","author":"Goldman","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/bs.acc.2015.10.005_bb0730","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/rheumatology\/33.2.199","article-title":"Simvastatin-associated dermatomyositis","volume":"33","author":"Khattak","year":"1994","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0735","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9343(01)00711-2","article-title":"Atorvastatin-induced dermatomyositis","volume":"110","author":"Noel","year":"2001","journal-title":"Am. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0740","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJM199208273270919","article-title":"Pravastatin-associated inflammatory myopathy","volume":"327","author":"Schalke","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0745","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mus.20127","article-title":"Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake","volume":"30","author":"Vasconcelos","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/bs.acc.2015.10.005_bb0750","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/bs.acc.2015.10.005_bb0755","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pone.0000097","article-title":"A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle","volume":"1","author":"Laaksonen","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2015.10.005_bb0760","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/bs.acc.2015.10.005_bb0765","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40279-014-0224-4","article-title":"The effects of statin medications on aerobic exercise capacity and training adaptations","volume":"44","author":"Murlasits","year":"2014","journal-title":"Sports Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0770","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1253\/circj.CJ-10-1240","article-title":"Prevention of atherosclerosis in overweight\/obese patients\u2014in need of novel multi-targeted approaches","volume":"75","author":"Lim","year":"2011","journal-title":"Circ. J."},{"key":"10.1016\/bs.acc.2015.10.005_bb0775","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1194\/jlr.P900029-JLR200","article-title":"Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study","volume":"50","author":"Monda","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2015.10.005_bb0780","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1249\/MSS.0b013e31821b4d0a","article-title":"Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction","volume":"43","author":"Chomistek","year":"2011","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/bs.acc.2015.10.005_bb0785","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2007.12.048","article-title":"Physical activity in statin-treated patients","volume":"134","author":"Mascitelli","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0790","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1123\/jpah.7.5.584","article-title":"No strain, no gain: psychosocial predictors of physical activity across the adult lifespan","volume":"7","author":"Cotter","year":"2010","journal-title":"J. Phys. Act. Health"},{"key":"10.1016\/bs.acc.2015.10.005_bb0795","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(12)61426-3","article-title":"Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study","volume":"381","author":"Kokkinos","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0800","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database","volume":"51","author":"Barter","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2015.10.005_bb0805","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacc.2013.02.074","article-title":"Simvastatin impairs exercise training adaptations","volume":"62","author":"Mikus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0810","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1152\/japplphysiol.01362.2011","article-title":"Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance","volume":"113","author":"Muraki","year":"1985","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0815","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0820","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0825","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bjornsson","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0830","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/bs.acc.2015.10.005_bb0835","doi-asserted-by":"crossref","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0840","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4065\/mcp.2009.0365","article-title":"Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma","volume":"85","author":"Calderon","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/bs.acc.2015.10.005_bb0845","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data\u20142005","volume":"97","author":"Bays","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0850","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/CIRCULATIONAHA.105.555482","article-title":"The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis","volume":"111","author":"Alsheikh-Ali","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2015.10.005_bb0855","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1161\/CIRCULATIONAHA.105.557652","article-title":"The issue of statin safety: where do we stand?","volume":"111","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2015.10.005_bb0860","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000077704","article-title":"Rosuvastatin-induced arrest in progression of renal disease","volume":"102","author":"Vidt","year":"2004","journal-title":"Cardiology"},{"key":"10.1016\/bs.acc.2015.10.005_bb0865","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1097\/01.ASN.0000138236.82706.EE","article-title":"Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells","volume":"15","author":"Sidaway","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0870","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.301.6747.309","article-title":"Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials","volume":"301","author":"Muldoon","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/bs.acc.2015.10.005_bb0875","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/bmj.306.6889.1367","article-title":"Cholesterol lowering and mortality: the importance of considering initial level of risk","volume":"306","author":"Smith","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/bs.acc.2015.10.005_bb0880","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0140-6736(93)92556-9","article-title":"Plasma cholesterol and depressive symptoms in older men","volume":"341","author":"Morgan","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0885","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/archinte.163.16.1926","article-title":"Lipid-lowering drugs and the risk of depression and suicidal behavior","volume":"163","author":"Yang","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0890","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/qjmed\/hch035","article-title":"Severe irritability associated with statin cholesterol-lowering drugs","volume":"97","author":"Golomb","year":"2004","journal-title":"QJM"},{"key":"10.1016\/bs.acc.2015.10.005_bb0895","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1592\/phco.29.7.800","article-title":"Statin-associated adverse cognitive effects: survey results from 171 patients","volume":"29","author":"Evans","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/bs.acc.2015.10.005_bb0900","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0905","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.1996.03530250059028","article-title":"Carcinogenicity of lipid-lowering drugs","volume":"275","author":"Newman","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0910","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.20758","article-title":"Cancer risk among statin users: a population-based cohort study","volume":"114","author":"Friis","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.acc.2015.10.005_bb0915","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2004.02.027","article-title":"The risk of cancer in users of statins","volume":"22","author":"Graaf","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0920","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.amjmed.2007.12.011","article-title":"Statins and cancer risk","volume":"121","author":"Karp","year":"2008","journal-title":"Am. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0925","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0930","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bjc.6601566","article-title":"Statin use and cancer risk in the General Practice Research Database","volume":"90","author":"Kaye","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2015.10.005_bb0935","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jnci\/djj006","article-title":"Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort","volume":"98","author":"Jacobs","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.10.005_bb0940","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/djk003","article-title":"Statin use and risk of colorectal cancer","volume":"99","author":"Coogan","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.10.005_bb0945","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1001\/archinte.165.19.2264","article-title":"Serum lipids, lipid-lowering drugs, and the risk of breast cancer","volume":"165","author":"Eliassen","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0950","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0955","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb0960","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ijc.22366","article-title":"Statins and risk of cancer: a systematic review and metaanalysis","volume":"120","author":"Browning","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.acc.2015.10.005_bb0965","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2015.10.005_bb0970","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(04)16936-5","article-title":"Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)","volume":"364","author":"Strandberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0975","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"357","author":"Ford","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb0980","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)61125-2","article-title":"Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial","volume":"378","author":"Bulbulia","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb0985","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5551\/jat.E562","article-title":"Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus","volume":"15","author":"Yamakawa","year":"2008","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/bs.acc.2015.10.005_bb0990","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jacc.2004.04.050","article-title":"Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model","volume":"44","author":"Yu","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb0995","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.atherosclerosis.2005.05.009","article-title":"Atorvastatin induces insulin sensitization in Zucker lean and fatty rats","volume":"184","author":"Wong","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2015.10.005_bb1000","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1253\/circj.71.144","article-title":"Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes","volume":"71","author":"Chen","year":"2007","journal-title":"Circ. J."},{"key":"10.1016\/bs.acc.2015.10.005_bb1005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1507\/endocrj.K06-198","article-title":"Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia","volume":"54","author":"Mita","year":"2007","journal-title":"Endocr. J."},{"key":"10.1016\/bs.acc.2015.10.005_bb1010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/jc.2008-1750","article-title":"The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study","volume":"94","author":"Sathyapalan","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2015.10.005_bb1015","first-page":"1","article-title":"Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults","author":"Mansi","year":"2015","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb1020","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2012.05.019","article-title":"Statins, risk of diabetes, and implications on outcomes in the general population","volume":"60","author":"Wang","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb1025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.10.005_bb1030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0014-4835(90)90012-J","article-title":"On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors","volume":"50","author":"Gerson","year":"1990","journal-title":"Exp. Eye Res."},{"key":"10.1016\/bs.acc.2015.10.005_bb1035","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1001\/archinte.161.16.2021","article-title":"Risk of cataract in patients treated with statins","volume":"161","author":"Schlienger","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2015.10.005_bb1040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/qjmed\/hcg064","article-title":"Cataract and the use of statins: a case-control study","volume":"96","author":"Smeeth","year":"2003","journal-title":"QJM"},{"key":"10.1016\/bs.acc.2015.10.005_bb1045","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1001\/jama.295.23.2752","article-title":"Statin use and incident nuclear cataract","volume":"295","author":"Klein","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2015.10.005_bb1050","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/bjo.79.11.996","article-title":"Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group","volume":"79","author":"Harris","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/bs.acc.2015.10.005_bb1055","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database","volume":"340","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/bs.acc.2015.10.005_bb1060","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jamaophthalmol.2013.4575","article-title":"Association of statin use with cataracts: a propensity score-matched analysis","volume":"131","author":"Leuschen","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/bs.acc.2015.10.005_bb1065","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2000.7716a","article-title":"Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia","volume":"49","author":"Dobs","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/bs.acc.2015.10.005_bb1070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(96)00742-4","article-title":"The efficacy and six-week tolerability of simvastatin 80 and 160mg\/day","volume":"79","author":"Davidson","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2015.10.005_bb1075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/s-2007-979159","article-title":"Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment","volume":"28","author":"Azzarito","year":"1996","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/bs.acc.2015.10.005_bb1080","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5551\/jat.10.160","article-title":"Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia","volume":"10","author":"Santini","year":"2003","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/bs.acc.2015.10.005_bb1085","first-page":"747","article-title":"Use of lipid-lowering agents (statins) during pregnancy","volume":"49","author":"Hosokawa","year":"2003","journal-title":"Can. Fam. Physician"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242315000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242315000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:32:51Z","timestamp":1758742371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242315000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9780128046906"],"references-count":217,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2015.10.005","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}